Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation
| Autor: | Pamela A Jacobson, Cheryl Cadotte, David J. Edwards, Rami B. Ibrahim, Jason Mulawa, Simon Cronin, Muneer H. Abidi, Daryn Smith, Joseph P. Uberti, Lois Ayash |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Antifungal Agents Adolescent Morpholines medicine.medical_treatment Hematopoietic stem cell transplantation Pharmacology Tacrolimus Young Adult Liver Function Tests medicine Humans Drug Interactions Pharmacology (medical) Clinical significance Fluconazole Aprepitant Retrospective Studies Dose-Response Relationship Drug CYP3A4 medicine.diagnostic_test business.industry Hematopoietic Stem Cell Transplantation Middle Aged Discontinuation Dose–response relationship Mycoses Oncology Injections Intravenous Antiemetics Female business Liver function tests Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Oncology Pharmacy Practice. 14:113-121 |
| ISSN: | 1477-092X 1078-1552 |
| Popis: | Aprepitant (AP) is a known inhibitor of cytochrome P450 3A4 which may affect tacrolimus metabolism. We retrospectively examined the effect of oral AP on intravenous tacrolimus concentrations in 26 patients undergoing reduced intensity transplantation from 09/2005 to 09/2006. Oral AP 125 mg daily was administered on transplant day +1 and 80 mg on days +2 and +3. Intravenous tacrolimus was administered as a 0.03 mg/kg/day continuous infusion on day -6 through day +1 (pre-AP), during-AP (days +2 to +7), and post-AP starting on day +8. Tacrolimus doses were adjusted to achieve concentrations of 5—20 ng/mL. Dose-corrected tacrolimus concentrations (ng/mL/mg per dose) in the pre-AP, during-AP, and post-AP time periods were: 8.12 (95% CI: 7.3—9.1), 11.63 (95% CI: 9.63—13.63), and 11.42 (95% CI: 8.12—14.7), respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|